Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study.

J Clin Med · 2024 · PMC11508498 · PMID 39458170

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

might be significantno p-value reported

The bias determined by the retrospective, multicentre, and real-world nature of the study might be significant.

also in 2,457 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.